[HTML][HTML] Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model
Blockade of the B7: CD28 costimulatory pathway has emerged as a promising therapy to
prevent allograft rejection. However, results from the belatacept phase III clinical trial
demonstrated a higher rejection rate when compared to cyclosporine, raising concern about
potential deleterious effects of this agent. In this study, we investigated the consequences of
B7: CD28 blockade by hCTLA4Ig on regulator T cell (Treg) generation in different major
histocompatibility complex (MHC) mismatch transplant models. Administration of hCTLA4Ig …
prevent allograft rejection. However, results from the belatacept phase III clinical trial
demonstrated a higher rejection rate when compared to cyclosporine, raising concern about
potential deleterious effects of this agent. In this study, we investigated the consequences of
B7: CD28 blockade by hCTLA4Ig on regulator T cell (Treg) generation in different major
histocompatibility complex (MHC) mismatch transplant models. Administration of hCTLA4Ig …